How quickly things can change when Congress is trying to shuffle out of D.C. for a month in a midterm election year and huge issues are stacking up like airplanes on a tarmac.
The legislation that was once known as “Build Back Better” on Thursday became the “Inflation Reduction Act.” This new complex package of tax increases, subsidies for people who get insurance through the Affordable Healthcare Act and tax increases on corporations will come before a Senate vote next week.
One week ago today, I told you that in a matter of weeks, millions of Americans who get their health insurance through the Affordable Care Act’s insurance marketplace will be getting a letter in the mail telling them that their health insurance costs, in some cases, will double. In even more cases, the premiums will rise by more than $100 a month.
That would happen if Congress does not extend the insurance subsidies in place now. The subsidies expire at the end of the year. Until Wednesday evening, it appeared the subsidies might become a heated midterm election issue. But Senator Joe Manchin, D-W.Va., who a week ago wavered in his tie-breaking support for extending the subsidies, now agrees that the nation should extend the federal subsidies for Affordable Care Act premiums, first enacted by the American Rescue Plan for three years. That does not make the subsidies permanent, but that is another issue for another Congress.
It is difficult to overstate how important this is, despite so little news coverage of this issue. Bloomberg points out:
The framework’s ACA subsidy extension comes as the share of Americans who rely on the ACA continues to grow. A new report the CDC published this morning shows the share of Americans without health coverage continued to fall in the first quarter to 8%, or 26.4 million people— down from 9.5%, or 30.8 million, in the first quarter of 2021. In April, HHS reported that total enrollment for Medicaid expansion, ACA marketplace coverage, and the Basic Health Program reached an all-time high of over 35 million people in early 2022, Sara Hansard reports.
The Kaiser Family Foundation provides a deep dive into this issue including probable increases if the subsidies are not extended (though it appears now they will be.) But journalists, remember that just as we have witnessed this week, in a midterm election year, things change quickly and sometimes in a heated way. Stay alert.
The ‘Inflation Reduction Act’ promises to lower some drug prices eventually
Without a doubt, lawmakers who vote for President Joe Biden’s plan will crow that they voted to lower drug prices. If the bill passes and becomes law, not much will change for most people for years. A major part of that claim will be embodied by saving $288 billion through prescription drug pricing reforms. The reforms include two major measures including allowing Medicare to negotiate drug prices and capping out-of-pocket costs to $2,000.
As I said, drug prices are not going to drop fast, even under the new plan before the Senate. It is a six-year process that begins next year, then the cap on out-of-pocket prescriptions for Medicare kicks in in 2025. Then, 10 or 15 drugs at a time, Medicare will negotiate with drug companies for lower prescription prices for some costly drugs. The Kaiser Family Foundation explains the timeline: